KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).

被引：2
|
作者：
Lee, Chung-Han
Li, Chenxiang
Perini, Rodolfo F.
Hoehn, Daniela
Albiges, Laurence
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS4595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4595
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) plus lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)
    Albiges, L.
    Gurney, H. P.
    Atduev, V.
    Suarez, C.
    Climent Duran, M. A.
    Pook, D.
    Tomczak, P.
    Barthelemy, P.
    Lee, J-L.
    Nalbandian, T.
    Stus, V.
    Ferguson, T.
    Wiechno, P.
    Gokmen, E.
    Lacombe, L.
    Gedye, C.
    Perini, R.
    Sharma, M.
    Li, C.
    Lee, C-H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1204 - S1204
  • [2] First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.
    Voss, Martin H.
    Gurney, Howard
    Atduev, Vagif
    Suarez, Cristina
    Climent, Miguel Angel
    Pook, David William
    Tomczak, Piotr
    Barthelemy, Philippe
    Lee, Jae-Lyun
    Nalbandian, Taron
    Stus, Viktor
    Ferguson, Thomas
    Wiechno, Pawel
    Gokmen, Erhan
    Lacombe, Louis
    Gedye, Craig
    Burgents, Joseph E.
    Sharma, Manish
    Cornell, Jerry
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 2 - 2
  • [3] First-line lenvatinib plus pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.
    Lee, Chung-Han
    Gurney, Howard
    Atduev, Vagif
    Suarez, Cristina
    Duran, Miguel A. Climent
    Pook, David William
    Tomczak, Piotr
    Barthelemy, Philippe
    Lee, Jae-Lyun
    Nalbandian, Taron
    Stus, Viktor
    Ferguson, Thomas
    Wiechno, Pawel
    Gokmen, Erhan
    Lacombe, Louis
    Gedye, Craig
    Burgents, Joseph
    Sharma, Manish
    Peng, Xiang
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61) a single-arm, multicentre, phase 2 trial 
    Albiges, Laurence
    Gurney, Howard
    Atduev, Vagif
    Suarez, Cristina
    Climent, Miguel A.
    Pook, David
    Tomczak, Piotr
    Barthelemy, Philippe
    Lee, Jae Lyun
    Stus, Viktor
    Ferguson, Thomas
    Wiechno, Pawel
    Gokmen, Erhan
    Lacombe, Louis
    Gedye, Craig
    Perini, Rodolfo F.
    Sharma, Manish
    Peng, Xiang
    Lee, Chung-Han
    LANCET ONCOLOGY, 2023, 24 (08): : 881 - 891
  • [5] First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.
    McDermott, David F.
    Lee, Jae-Lyun
    Ziobro, Marek
    Gafanov, Rustem Airatovich
    Matveev, Vsevolod Borisovich
    Suarez, Cristina
    Donskov, Frede
    Pouliot, Frederic
    Alekseev, Boris Y.
    Wiechno, Pawel
    Tomczak, Piotr
    Duran, Miguel Angel Climent
    Shin, Sang Joon
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Schloss, Charles
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
    McDermott, David F.
    Lee, Jae-Lyun
    Ziobro, Marek
    Suarez, Cristina
    Langiewicz, Przemyslaw
    Matveev, Vsevolod Borisovich
    Wiechno, Pawel
    Gafanov, Rustem Airatovich
    Tomczak, Piotr
    Pouliot, Frederic
    Donskov, Frede
    Alekseev, Boris Yakovlevich
    Shin, Sang Joon
    Bjarnason, Georg A.
    Castellano, Daniel
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Schloss, Charles
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (09)
  • [7] First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B
    Suarez, C.
    Lee, J-L.
    Ziobro, M.
    Gafanov, R. A.
    Matveev, V. B.
    Donskov, F.
    Pouliot, F.
    Alekseev, B. Y.
    Wiechno, P. J.
    Tomczak, P.
    Climent, M. A.
    Shin, S. J.
    Silverman, R. Kloss
    Perini, R. F.
    Schloss, C.
    McDermott, D. F.
    Atkins, M. B.
    ANNALS OF ONCOLOGY, 2019, 30 : 381 - 381
  • [8] Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
    Laramee, Sophie
    Ghosh, Sunita
    Kollmannsberger, Christian K.
    Hansen, Aaron Richard
    Wood, Lori
    Soulieres, Denis
    Canil, Christina M.
    Saleh, Ramy
    Castonguay, Vincent
    Bjarnason, Georg A.
    Basappa, Naveen S.
    Breau, Rodney H.
    Heng, Daniel Yick Chin
    Pouliot, Frederic
    Kapoor, Anil
    Lalani, Aly-Khan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.
    Lee, Jae-Lvun
    Ziobro, Marek
    Suarez, Cristina
    Langiewitz, Przemyslaw
    Matveev, Vsevolod Borisovich
    Wiechno, Pawel
    Gafanov, Rustem
    Tomczak, Piotr
    Pouliot, Frederic
    Donskov, Frede
    Alekseev, Boris
    Shin, Sang Joon
    Bjarnason, Georg A.
    Castellano, Daniel
    Du, Xiaoqi
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    McDermott, David F.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC)
    Hutson, Thomas E.
    Michaelson, M. Dror
    Kuzel, Timothy M.
    Agarwal, Neeraj
    Molina, Ana M.
    Hsieh, James J.
    Vaishampayan, Ulka N.
    Xie, Sharon
    Bapat, Urmi
    Jain, Rohit K.
    Fishman, Mayer N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345